Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zila in Europe

This article was originally published in The Tan Sheet

Executive Summary

Zila Nutraceuticals has entered a European distribution agreement for its Ester-C vitamin C ingredient with Gee Lawson, a London-based raw materials supplier, Zila announces May 26. The agreement with Gee Lawson would expand Ester-C's distribution across most of Europe, versus the previous arrangement that limited distribution to the UK, according to the Phoenix, Ariz.-based health products firm. Zila currently has an existing agreement for the vitamin C formulation in the Scandinavian region with Naturkost...

You may also be interested in...



Zila Ponders Sale Of Nutraceutical Division

Zila, Inc., the Phoenix-based maker of branded ingredient Ester-C, is considering selling its nutraceutical division, a move its executives say would allow them to focus on their burgeoning pharmaceutical and biotechnology areas

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.

Topics

UsernamePublicRestriction

Register

PS099422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel